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Abstract Although cyclophilin A (CypA) has been
reported to be over-expressed in cancer cells and solid
tumors, its expression and role in glioblastomas have not
been studied. Herein, we show that expression of CypA in
human glioblastoma cell lines and tissues is signiﬁcantly
higher than in normal human astrocytes and normal coun-
terparts of brain tissue. To determine the role of over-
expressed CypA in glioblastoma, stable RNA interference
(RNAi)-mediated knockdown of CypA (CypA KD) was
performed in gliobastoma cell line U87vIII (U87MG  
DEGFR). CypA KD stable single clones decrease
proliferation, inﬁltration, migration, and anchorage-inde-
pendent growth in vitro and with slower growth in vivo as
xenografts in immunodeﬁcient nude mice. We have also
observed that knockdown of CypA inhibits expression of
interleukin-8 (IL-8), a tumorigenic and proangiogenic cyto-
kine. Conversely, enforced expression of CypA in the CypA
KD cell line,Ud-12, markedly enhanced IL-8 transcriptsand
restoredUd-12proliferation,suggestingthatCypA-mediated
IL-8productionprovidesagrowthadvantagetoglioblastoma
cells.CypAknockdown-mediatedinhibitionofIL-8isdueto
reduced activity of NF-jB, which is one of the major tran-
scriptionfactorsregulatingIL-8expression.Theseresultsnot
only establishthe relevance of CypA to glioblastoma growth
in vitro and in vivo, but also suggest that small interfering
RNA-based CypA knockdown could be an effective thera-
peutic approach against glioblastomas.
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Introduction
Malignant gliomas are among the most devastating of
cancers, leading to death in most cases [1]. They present
unique challenges for therapy due to their difﬁcult access
locations, aggressive biological behavior, and diffuse
inﬁltrative growth. Cyclosporin A (CsA) has been reported
to have a chemotherapeutic effect in a variety of cancer
cells, including human gliomas [2–4]. In a human glio-
blastoma cell line and glioblastoma cells from brain slices,
CsA was shown to affect their growth/survival and
migration/invasion [3, 4]. The mechanisms of these effects
may relate to the biochemical properties of CsA such as
inhibition of cyclophilin isomerase and calcineurin
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effects that can alter several signal pathways.
CypA is found in normal cells, comprises *0.6% of total
cytosolic protein, and is widely conserved among pro-
karyotes and eukaryotes [5]. It is a member of the peptidyl-
prolyl isomerase (PPI) family, a group of proteins that
catalyze cis-trans isomerization of peptidyl-prolyl bonds
during protein folding and/or conformational changes [6,7].
CypA was ﬁrst identiﬁed as the primary intracellular target
of the immunosuppressive drug, CsA [8]. The immuno-
suppressive activity of CsA is thought to result from
engagement of calcineurin by the CsA-CypA complex [9],
an observation supported by the ﬁnding that CypA knock-
out mice are resistant to immunosuppression by CsA [10].
Several lines of research have revealed that PPIs such as
CypA may function as molecular signaling ‘‘switches’’ that
can act as novel molecular timers to help control the
amplitude and duration of a cellular process [11]. Moreover,
the role of CypA nuclear translocation or CypA’s partici-
pation in activation of other factors or their nuclear trans-
location also impacts various cellular functions [12–15].
One recent report demonstrated that knockdown of CypA
inhibited signal transducer and activator of transcription 3
(Stat3) interleukin-6-induced tyrosine phosphorylation and
nuclear translocation, resulting in altered gene expression in
myeloma cell lines [16]. The CypA inhibitor, CsA, exhib-
ited similar effects. Additional data also suggest that CypA
may contribute to the pathology of certain human malig-
nancies. Several experiments have demonstrated that CypA
is substantially up-regulated in various types of cancers and
cancer cell lines [17–20]. These over-expressed CypAs
mediate multiple cellular processes that can confer growth
advantage to tumor cells in the neoplastic microenviron-
ment. This was substantiated by CypA over-expression in
the SILEK-transformed small airway epithelial cell line,
which showed that increased CypA expression correlated
with dramatically faster tumor formation in vivo [21].
Furthermore, CypA over-expression in cancer cells con-
ferred resistance to anticancer drugs and hypoxia-induced
cell death [22, 23]. Therefore, targeted CypA and inhibition
of its PPI activity have been suggested as novel therapeutic
strategies for treatment of human cancers.
Over-expression of CypA has also been implicated in
other pathological processes such as rheumatoid arthritis
[24, 25]. In rheumatoid arthritis patients, over-expressed
CypA stimulates production of inﬂammatory cytokines
such as tumor necrosis factor alpha (TNF-a), interleukin-
1b (IL-1b), IL-8, monocyte chemoattractant protein-1
(MCP-1), and matrix metalloproteinase 9 (MMP-9) [25].
These CypA-stimulated products could arise through a
pathway that is dependent on NF-jB activation. However,
the means by which CypA mediates signaling to activate
NF-jB remains to be investigated. Similarly, stably
expressed CypA in the SK-Hep1 cell line revealed that
CypA up-regulates the expression of many cytokine-related
genes such as IL-8, IL-1b, IL-6, CXCL1, CXCL2, and
CXCL3 [22]. These up-regulated cytokines and chemo-
kines may confer tumor cell growth advantage in the
neoplastic microenvironment. Therefore, a strategy to
reverse these effects might offer attractive options for
novel therapeutics.
In human gliomas, IL-8 is expressed and secreted at
high levels both in vitro and in vivo, and recent experi-
ments suggest it is critical to glial tumor neovascularity and
progression [26]. IL-8 could act as an inﬂammatory che-
moattractant as part of the host response to neoplasia.
Moreover, it also acts as a more general proinﬂammatory
factor released in response to tissue stress and necrosis, a
proangiogenic factor that promotes new vessel growth, or
an autocrine growth factor secreted by tumor cells to pro-
mote their own growth. Secretion of IL-8 could also arise
from any other cellular compartments such as microglia,
macrophages, and neutrophils. IL-8 gene expression and
peptide secretion by glioblastoma cells can be dramatically
enhanced by TNF-a and IL-1 [27, 28]. The IL-8 promoter
contains binding sites for transcription factors NF-jB, AP-
1, and C-EBP/NF-IL-6, among others, which are mediated
to respond to hypoxia, Fas ligation, death receptor activa-
tion, cytosolic calcium, TNF-a, IL-1, other cytokines, and
various cellular stresses increase IL-8 expression [29–31].
Expression of CypA and its relationship to highly
expressed IL-8 in glioblastoma has not been studied. Herein
we report that CypA was strongly expressed in a majority of
human glioblastomas and cell lines we tested. This ubiq-
uitous over-expression of CypA in glioblastoma suggests
that CypA could be an important component of neoplastic
transformation. To determine the role of over-expressed
CypA in glioblastoma, stable RNA interference (RNAi)-
mediated knockdown of CypA (CypA KD) in a gliobastoma
cell line was performed. The CypA KD stable single clones
showed decreased proliferation, inﬁltration, migration, and
anchorage-independent growth in vitro, as well as slower
tumor growth in vivo. The reversal of the tumor phenotype,
and in particular, decreased cell proliferation and slow
tumor growth, in CypA KD clones was associated with
reduced NF-jB activity and down-regulated IL-8 expres-
sion. Thus, targeted knockdown of CypA could be an
effective therapeutic approach for glioblastomas.
Materials and methods
Cell culture and cell proliferation assay
Human glioblastoma cell lines U87vIII, U87MG, T98G,
Ln229, U138, U378 and immortalized normal human
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123astrocytes were grown in DMEM with low glucose and
supplemented with 10% fetal bovine serum. Panc-1 and
A549 cells were purchased from ATCC. Panc-1 and A549
cells were cultured in DMEM and RPMI 1640 (Gibco),
respectively. Cells were maintained at 37C in a humidiﬁed
chamber containing 5% CO2. Cell proliferation was
assessed by the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-
tetrazolium bromide (MTT) method (MTT cell prolifera-
tion assay, ATCC). Cells (1500/well) were seeded in
triplicate into 96-well plates and cultured for various
periods. At each time point, 10 ll of MTT reagent was
added to each well and incubated for 2 h, followed by
addition of 100 ll of detergent reagent to each well for
additional 3 h incubation in the dark. At the end of the
reaction, the absorbance in each well was measured at
595 nm in a microtiter plate reader (BIO-TEK). Control
wells of medium alone were used as blanks. For the rescue
experiments, cells were transfected with vector alone or
rescue construct, using lipofectamine 2000 (Invitrogen).
Cells were then seeded into 96-well plates 18 h post-
transfection. Time zero (0 day) was 6 h after seeding.
Immunohistochemistry staining
A GL802 tissue microarray was purchased from U.S. Bio-
max, Inc. (Rockville, MD). It contains 35 samples of glio-
blastoma (grade IV), two samples of adjacent normal tissue,
and three samples of normal brain tissue from autopsies,
with a duplicate core per sample format. The tissues were
formalin-ﬁxed and parafﬁn-embedded. Array sections were
mounted on the positively charged glass slide. Tissue sec-
tions were deparafﬁnized, hydrated, and hybridized with
rabbit anti-cyclophilin A antibody (Abcam), followed by
incubation of sections with ImmPress anti-rabbit Ig (Vector
Lab). After washing the slides three times in buffer 5 min
each time, the sections were incubated in peroxidase sub-
strate DAB solution until desired stain intensity developed.
Counterstaining with hematoxylin was used for blue col-
oring of negative nuclei.
Xenograft tumor formation
All animal work described herein was approved by the
Chancellor’s Animal Research Committee at UCLA. Fol-
lowing determination of absence of mycoplasma contami-
nation by nucleic acid hybridization, one million cells each
of two CypA KD single clones, Ud-12 and Ud-3, scram-
bled clone (SC), and parental U87vIII were injected in
100 ll DMEM subcutaneously into the ﬂank of 4-week-
old, female, NCRU-M immunodeﬁcient mice (Taconic
Farms Inc, Hudson, New York); three animals per cell line
were used. Tumor dimensions were measured every
2–3 days with calippers and volume was calculated by the
formula V = 0.5 9 L 9 W
2, where L is long diameter and
W is short diameter.
Reverse transcription and quantitative real-time
PCR analysis
Total RNA was isolated from cells, using TRIzol reagent
(Invitrogen) according to the manufacturer’s protocols.
One microgram of total RNA was used for cDNA syn-
thesis, using Superscript III (Invitrogen) with an oli-
go(dT)15 primer. Quantitative real-time PCR (QRT-PCR)
was performed using the Power SYBR Green PCR Master
Mix (Applied Biosystem) and detected by the 7300 Real
Time PCR System (Applied Biosystem). The relative
expression of IL-8 mRNA normalized to the internal ref-
erence 18S rRNA was analyzed using the 2T
-DDC method
[32]. The amount of IL-8 transcripts in U87vIII cells, or
U87vIII cells transfected with vector alone, was designated
as 1.0. Bars indicate the standard error from three indi-
vidual experiments. The primers used for real-time PCR
were: IL-8,5 0-GGGTTGTGGAGAA-GTTTTTG-30 (for-
ward), 50-GTTTCACTGGCATCTTCACTG-30 (reverse);
18S rRNA,5 0-A-GTTGGTGGAGCGATTT-GTC-30 (for-
ward), 50-TATTGCTCAATCTCGGGTGG-30 (reverse).
Scratch-induced migration assay
U87vIII, Ud-3, and scrambled clone were separately see-
ded onto six-well plates at a density of 5 9 10
5 per well.
After 24 h, conﬂuent monolayers were scratched with a
1 ml plastic pipet tip to create a uniform, cell-free area.
Then the cells were incubated at 37C and photographed at
time points 0, 16, and 24 h on an Olympus IX71 inverted
microscope using an UPlanFL 49/0.13 N.A. PhL objective
(Olympus). Digital images were acquired with a MicroFire
digital camera driven by the PictureFrame imaging soft-
ware. The distance between the opposing edges was mea-
sured using the Adobe PhotoShop software.
Matrigel inﬁltration assay
An inﬁltration assay was performed using a six-well plate
transwell insert with 8-lm pore size ﬁlters (Fisher Scien-
tiﬁc) coated with Matrigel (BD Biosciences). Cells
(5 9 10
5) from cell lines U87vIII, Ud-3, Ud-12, and
scrambled clone containing 1.5 ml of serum-free DMEM
medium, were separately placed into each transwell insert.
Each well in the lower chambers was ﬁlled with 2.5 ml of
DMEM medium containing 10% fetal bovine serum (FBS).
After 24 h of incubation at 37C in a cell culture chamber,
the cells on the top surface of the ﬁlter were wiped off with
cotton swabs. Inﬁltrated cells on the lower surface of the
J Neurooncol (2011) 101:1–14 3
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Scientiﬁc). Random ﬁelds were counted under a light
microscope. Olympus microsuite
TM B3SV software was
used for photographing.
Anchorage-independent growth in soft agar
To evaluate the ability of individual cell lines to grow in an
anchorage-independent manner, 3000 cells from each cell
line (U87vIII, Ud-3, Ud-12, and scrambled clone) were
each mixed with 0.5 ml of UltraPure
TM Agarose (invitro-
gen) in DMEM medium with 10% FBS (ﬁnal concentration
0.3%), then overlayed with 1 ml of 0.6% agarose per well
of six-well plates (in duplicate). The cells were given
0.5 ml of 10% FBS DMEM per well every 5 days, and
incubated for 21 days, then stained by crystal violet. Col-
onies were counted using a microscope.
IL-8 ELISA
IL-8 ELISA was performed using the Endogen
 Human
IL-8 ELISA Kit (Thermo Scientiﬁc, Inc.) In brief, cells
were seeded into 24-well plates 24 h prior to assay, then
treated with different chemicals, as described in the
Results. Supernatants from cells were collected and ana-
lyzed for IL-8 levels according to the manufacturer’s
instructions. Absorbance was then measured on an ELISA
plate reader set at 450 nm and 550 nm. To correct for
optical imperfections on the microplate, 550-nm values
were subtracted from 450-nm values. The test samples
multiply the interpolated value obtained from the standard
curve by a dilution factor to calculate pg/ml of human IL-8
in the sample.
Electrophoretic mobility shift assay (EMSA)
Nuclear extracts were prepared using NE-PER nuclear and
cytoplasmic extraction reagents (Pierce Biotechnology).
EMSA was performed using the Light Shift Chemilumi-
nescent EMSA Kit (Pierce Biotechnology) according to the
manufacturer’s directions. In brief, the biotin end-labeled
probe (100 fmol) was incubated with nuclear extract
(15 lg) and electrophoresed on a native polyacrylamide
gel. The DNA was then transferred to a nylon membrane,
UV cross-linked, probed with the streptavidin-horseradish
peroxidase conjugate, and chemiluminescent substrate was
used for detection. The EMSA probes with 50 biotin labels
were purchased from Sigma-Aldrich. Nucleotide sequences
were as follows: NF-jB oligo, 50-AGTTGAGGGGAC-TT
TCCCAGGC-30; AP1 oligo, 50-CGCTTGATGAGTCAGC
CGGAA-30; C/EBP oligo, 50-GCCATCAGTTGCAAATC
GTGGC-30. For competition experiments, 100-fold molar
excess of unlabeled oligos were incubated with the protein
at 25C for 10 min before addition of labeled probes, and
then further incubated for 20 min.
Luciferase reporter assays
The luciferase reporter plasmids driven by -162 to ?44 of
human IL-8 promoter (p162-IL-8) and its mutants
(p162mtAP1, p162mtC/EBP, and p162mtNF-jB) were
kindly provided by James J. Pestka (Michigan State Uni-
versity). Cells were plated into 48-well plates and cultured
for 1 day, then transfected with 0.3 lg/well of reporter
plasmids and 0.006 lg/well Renilla luciferase plasmid,
using lipofectamine 2000 (Invitrogen). Fireﬂy and Renilla
luciferase activity were measured with the dual-luciferase
reporter assay system (Promega). Results are presented as
relative reporter activity after normalization to the Renilla
luciferase activity. For promoter activity at basal level,
cells were assayed 24 h post-transfection. For TNFa and
cyclosporin A (CsA) (Sigma-Aldrich) treatment, cells were
incubated with 1 lg/ml CsA for 5 h at 24 h post-trans-
fection, then stimulated with 10 ng/ml TNF-a for another
4 h. Cells were then harvested and promoter activity
determined.
Statistical analysis
Results are expressed as means ± SE from at least three
independent experiments. Statistical analysis was per-
formed using student’s t test. Unless otherwise indicated,
P\0.05 was deemed signiﬁcant.
Results
Elevated cyclophilin A (CypA) in human glioblastoma
cell lines and tissue specimens
CypA is substantially up-regulated in various types of
tumors and cancer cell lines [17–21]. To investigate whe-
ther elevated CypA at the protein level is also present in
glioblastoma cell line, U87MG and its EGFR deletion
mutant, U87vIII, and other glioblastoma cell lines, we
performed Western blot analysis of cell lysates prepared
from these cell lines and compared them to those isolated
from normal human astrocytes (NHA). Our data demon-
strate that CypA protein expression in glioblastoma cell
lines is signiﬁcantly higher than the control (Fig. 1a, lanes
1–3). This elevated CypA expression is comparable to that
seen in the human pancreatic cancer cell line, Panc-1 [17],
and the human lung epithelial carcinoma cell line, A549
[21] (Fig. 1a, lanes 4–14). These data clearly demonstrate
that CypA is over-expressed in all glioblastoma cell lines
we tested.
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lines with glioblastoma specimens, eleven human glio-
blastoma specimens and surrounding normal brain tissue in
each specimen were obtain from the laboratory of Dr.
Linda Liau (UCLA). Coomassie brilliant blue R250-
stained signals on the nitrocellulose membrane served as
internal controls prior to immunoblot analysis. As shown in
Fig. 1b, the human glioblastoma specimens had 2.1- to
13-fold increases in CypA protein levels compared to
adjacent normal tissue. About 73% of tumor tissues
examined contained over-expressed CypA, suggesting that
CypA could be involved in glioblastoma pathogenesis. In
addition, we obtained a GL802 tissue microarray from U.S.
Biomax, Inc. (Rockville, MD). Deparafﬁnized and hydra-
ted tissue sections were hybridized with rabbit anti-cyclo-
philin A antibody (AbCame), followed by incubation of the
sections with ImmPress anti-rabbit Ig (Vector Lab) and
DAB (brown) staining. Counterstaining with hematoxylin
was used for blue coloring of negative nuclei. CypA
immunohistochemical quantitation in glioblastoma multi-
forms (GBMs) is shown in Table 1. About 86% of tumor
tissues contained over-expressed CypA. A representative
CypA stain is shown in Fig. 1c.
CypA knockdown correlated with decreased cell
proliferation in vitro and slower tumor growth in vivo
Infection of U87vIII cells with the pSilencer-CypA RNAi
retrovirus vector yielded ﬁve stable single clones with
70–90% CypA knockdown (CypA KD), as quantitated by
chemiluminescence of Western blots (Fig. 2a). Among
these single clones, Ud-12 had the greatest CypA KD, and
the four other single clones (Ud-3, Ud-8, Ud-13 and Ud-15)
had lesser amounts. Single clones selected with pSilencer-
scrambled RNAi showed no differences in CypA levels
relative to parental U87vIII cells (Fig. 2a). To determine
whether the CypA KD single clones had an intrinsic effect
on cell proliferation, we performed MTT assays to measure
cell proliferation in the CypA KD single clones, Ud-3 and
Ud-12, and their parental and scrambled control cells. As
shown in Fig. 2b, a difference was noted between knock-
downs and parental cells and scrambled control cells. Thus,
we conclude that the CypA KD single clones Ud-3 and
Ud-12 led to decreased proliferation compared to parental
U87vIII and SC.
To determine whether CypA KD single clones have a
similar effect of slowing tumor growth in vivo, we grew
CypA KD clones as xenografts in immunodeﬁcient nude
mice. CypA KD cells Ud-3 and Ud-12 yielded slower-
growing tumors than control cells for the U87vIII cells and
SC (Fig. 2c). At 21 days, tumors from CypA KD Ud-12
and Ud-3 cells were, on average, 96 and 74% smaller,
respectively, than tumors from control cells. These results
indicate that CypA KD had a signiﬁcant effect on tumor
growth in vivo.
CypA KD decreases anchorage-independent growth,
cell migration and inﬁltration in vitro
To determine whether the CypA KD single clones can
reverse the transformed phenotype of glioblastoma, we
examined anchorage-independent growth of CypA KD,
scrambled and parental control cells, using a soft agar
assay. After 21 days of incubation, the cells were stained
with crystal violet and imaged. Colonies larger than
0.2 mm
2 were counted. Results of a typical experiment
Fig. 1 Over-expression of CypA in glioblastoma cell lines and
human tissue specimens. a Elevated CypA at the protein level in
glioblastoma cell lines. Five micrograms of cell lysate prepared from
U87MG and U87MG. DEGFR (U87vIII) and normal human astrocyte
(NHA) were subjected to Western blot analysis to detect CypA
expression levels (lanes 1–3). Actin was used as a loading control.
Over-expression of CypA levels in glioblastoma cell lines is
comparable with those in pancreatic and non-small cell lung
carcinoma cell lines (lanes 6 and 7). Lanes 8–11 are other
glioblastoma cell lines, and U87DK (lane 12) represents K721
mutation and kinase inactive at EGFR. b Relative CypA levels in
human glioblastoma and normal tissues. Ten micrograms of tissue
lysates were subjected to Western blot analysis. Coomassie brilliant
blue R250-stained signals on the nitrocellulose membrane served as
internal controls. (N, normal brain tissue; T, tumor tissue). c CypA
expression in glioblastoma multiforms (GBMs). Deparafﬁnized and
hydrated tissue sections were hybridized with rabbit anti-cyclophilin
A antibody (Abcam), followed by incubating sections with ImmPress
anti-rabbit Ig (Vector Lab) and DAB (brown) staining. Arrows
indicate typical positive staining for CypA. Non-neoplastic normal
cerebrum tissue and cancer-adjacent normal cerebrum tissue were
used as controls
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123showed that U87vIII cells and SC formed signiﬁcant
numbers of colonies in soft agar. The Ud-12 clone caused
signiﬁcant decreases in colony numbers (Fig. 3a); notably,
Ud-12 also decreased colony sizes. Taken together, these
results indicate that CypA KD inhibits anchorage-inde-
pendent growth of U87vIII cells. Thus, we concluded that
CypA KD attenuates the transformed phenotype of U87vIII
cells.
To investigate the effects of CypA KD on a second
manifestation of the transformed phenotype, cell motility
of glioblastoma cells, we performed a scratch-induced
migration assay. Subconﬂuent monolayers of CypA KD
single clones, parental U87vIII cells, and SC were woun-
ded at time 0 with a plastic scraper to create a cell-free
space 2 mm wide, and were monitored at 16 and 24 h after
wounding by photomicrograph. The U87vIII cells and SC
migrated into the cell-free region, and the wounded area
was nearly completely recovered after 24 h (Fig. 3b).
However, recovery of the wound area in the CypA KD Ud-
3 cells was only 50% at the same time point (Fig. 3b).
These results demonstrated that gap closure was strongly
attenuated in the CypA KD single clone, Ud-3, which
seemed to progress more slowly than the control cells.
Cell inﬁltration is similar to cell migration, but it
requires a cell to migrate through an extracellular matrix or
a basement membrane extract barrier, and then become
established in a new location. Transwell plates from
Corning Life Sciences provide a relatively simple approach
to performing cell inﬁltration assays in vitro. The effect of
CypA KD on cell inﬁltration was evaluated using Matrigel
as an extracellular matrix component. Chambers were
incubated for 24 h under normal cell culture conditions.
Invading cells on the lower side of the ﬁlter were stained
with 0.1% crystal violet (Fig. 3c) and quantiﬁed after dis-
solving the cell-bound crystal violet in 10% acetic acid (v/
v), followed by measurement of optical density at 540 nm
(Fig. 3c). Results are presented as the relative OD 540 nm
reading.
CypA KD increases apoptosis under the condition
of serum withdrawal
It has been reported that over-expression of CypA protects
cells from apoptosis [23]. To determine whether CypA KD
would sensitize cells to apoptosis under stress conditions,
we used a well-established in vitro model, serum with-
drawal, to induce apoptosis. The CypA KD single clones,
Ud-3 and Ud-12, and parental U87vIII control cells were
grown in 96-well plates in media without serum for 6 days.
At different time points, cells were subjected to MTT
assays to measure cell viability. After 6 days, greater cell
death was observed in the KD cells than in the control cells
(Fig. 4). As shown in Fig. 4, viable cells of the CypA KD
clones, Ud-3 and Ud-12, are signiﬁcantly reduced on day 6,
suggesting that KD cells are more sensitive to serum
withdrawal than the control cells.
Table 1 CypA expression in GBMs
Bank case number Cypa (set 1) Cypa (set2)
CT CT
1 -?
2 -?
3 --
4 --
A1 ??? ???
A2 ?? ???
A3 ?? ??
A4 ??? ????
A5 ??? ???
B1 ?? ???
B2 ??? ???
B3 ??? ???
B4 ? ????
B5 ?? ?
C1 ?? ???
C2 ??? ??
C3 ??? ???
C4 - ???
C5 ?? ??
D1 ??? ???
D2 ?? ??
D3 ???? ????
D4 ??
D5 ??? ???
E1 ?? ?
E2 ???? ????
E3 ???? ????
E4 ??? ???
E5 ???? ????
F1 --
F2 ?? ?
F3 ?? ?
F4 ?? ??
F5 ???? ????
G1 ???? ????
G2 ???? ????
G3 ??? ???
G4 ??? ????
G5 ??? ???
CypA immunohistochemical quantitation in GBMs. C normal cere-
brum tissue; T tumor. Scoring: -, no staining; ?, staining of less 10%
of cells, ??, staining of 20–30% of cells; ???, staining of 30–60%
of cells; ????, staining of greater than 60% of cells
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signiﬁcantly reduces IL-8 expression
To determine whether CypA KD can affect expression of
cytokines such IL-8 in the glioblastoma cell line, U87vIII,
real-time RT-PCR was performed to assess cytokine
expression in the CypA KD single clones, Ud-12 and Ud-3,
as compared to its parental cells and scrambled clone. As
shown in Fig. 5a, expression of IL-8 in Ud-12 and Ud-3
cells was signiﬁcantly decreased by 90 and 80%, respec-
tively, as compared with parental U87vIII control cells. To
determine whether down-regulated IL-8 occurs at the pro-
tein level, we performed ELISA assays using the Endo-
gen Human IL-8 ELISA Kit (Thermo Scientiﬁcs Inc). As
shown in Fig. 5b, the levels of IL-8 expression in the CypA
KD clones, Ud-12 and Ud-3, were 98 and 90% lower than
parental U87vIII cells. Thus, this observation is very
important regarding reversal of tumor phenotype.
Rescue of the knockdown phenotype restores IL-8
expression and cell proliferation
To ensure that the observed knockdown phenotype
described above is the result of silencing CypA, the
intended target, we introduced siRNA-resistant wild-type
CypA with myc-tagged plasmid into Ud-12 cells to reverse
siRNA effects. Western blot analysis indicated that exog-
enous myc-tagged CypA was expressed in Ud-12 cells at
levels similar to endogenous CypA in wild-type cells
(Fig. 6a). We then analyzed their effects on IL-8 expres-
sion and cell proliferation. Results shown in Fig. 6b and c
demonstrate that re-introduction of wild-type CypA
restored the decreased IL-8 levels and cell proliferation
caused by CypA RNAi, indicating that these defects were
due to a reduction of CypA. As reported previously, CypA
may contribute to proliferation, the inﬂammatory process,
and angiogenesis mediated through activation of cytokine
IL-8 [22, 25]. The mechanism for CypA activation of IL-8
and CypA KD reversal remains to be elucidated.
Identiﬁcation of CypA-associated transcription factor(s)
in regulation of IL-8 expression in U87vIII cells
CypA KD inhibits IL-8 expression at both the mRNA and
protein levels, suggesting that inhibition of IL-8 expression
occurs at the transcriptional level. Although CypA is not a
transcription factor and has no DNA-binding motif in
the promoter of the IL-8 gene, CypA-associated IL-8
Fig. 2 CypA KD single clones result in decreased cell proliferation
and tumor growth. a CypA KD stable single clones generated from
U87vIII cells. U87vIII cells were seeded into 24-well plates at
5 9 10
4 cells per well 1 day before infection with enriched viral
media prepared from the CypA-speciﬁc siRNA insert, scrambled
siRNA vector, and linearized retrovirus vector (supplied with the
pSilencer H1-Retro kit purchased from Ambion). Cells were trans-
ferred into 6-well plates 3 days post-infection and selected with
2 lg/ml puromycin for 2 weeks. Puromycin-resistant clones were
harvested and lysed with RIPA buffer supplemented with a protease
inhibitor cocktail (Sigma). Five micrograms of total protein was used
for Western blot analysis. Membranes probed with actin antibody
were used as loading controls. b CypA KD results in decreased cell
proliferation. Ud-3 and Ud-12 were compared to parental U87vIII
cells and scrambled clone (SC), using MTT assays according to the
manufacturer’s protocol. Values of OD 595 absorbance at each time
point were the average of triplicate individual readings (bars, SE; *,
P\0.05 compared with parental wild-type cells). c CypA KD
decreases tumor growth. Taconic Balb/c/NIH(s) female nu/nu mice
were used for xenografts. One million cells were injected. At each
time point, tumor dimensions were measured with calipers, and
volume was calculated as V= 0.5 9 L 9 W
2. Three mice were used at
each time point and each cell type (bars, SE; *, P\0.05 compared
with parental wild-type cells)
c
J Neurooncol (2011) 101:1–14 7
123expression may be regulated by transcription factors such
as NF-jB, C/EBP, and AP1, which are important in the
regulation of IL-8 expression. We used a wild-type and a
series of mutant IL-8 promoter luciferase constructs to
assess the regulation of IL-8 expression in U87vIII cells
mediated by the above transcription factor-binding sites.
U87vIII cells were transiently transfected with a -162-bp
IL-8 promoter construct and mutation constructs containing
AP-1 (-126 to -120), C/EBP (-94 to -81), or NF-jB
(-80 to -70) site mutations for 48 h, and then assayed for
luciferase activity (Fig. 7a). As shown in Fig. 7b, mutation
of the NF-jB, C/EBP, or AP1 sites resulted in a signiﬁcant
Fig. 3 The CypA KD U87vIII single clone decreases anchorage-
independent growth, and reduces cell migration and inﬁltration ability
in vitro. a Anchorage-independent growth in vitro. Ud-12 and
parental U87vIII cells and SC were plated in duplicate in six-well
plates in 0.5% soft agarose on a 1.4% agarose bed agar medium. After
21 days of incubation, the cells were stained with crystal violet and
imaged. Colonies larger than 0.2 mm
2 were counted. Ud-12/U87vIII=
47.6%, P\0.05. b Knock down of CypA in U87vIII reduces cell
migration. Ud-3 cells were seeded into 6-well plates. When cells
reached subconﬂuent monolayers, a scratch wound was inﬂicted, and
the resulting gap was imaged at the time of the wound and after 16
and 24 h. Images are from a typical experiment. c Inﬁltration assay in
vitro. Transwell plates from Corning Life Sciences were used for
invasion assays. The effect of CypA KD on cell inﬁltration was
evaluated using Matrigel as an extracellular matrix component.
Chambers were incubated for 24 h under normal cell culture
conditions. Invading cells on the lower side of the ﬁlter were stained
with 0.1% crystal violet (left panel) and quantiﬁed after dissolving the
cell-bound crystal violet in 10% acetic acid (v/v), followed by
measurement of optical density at 540 nm. (Columns, mean of the
relative OD 540 nm readings from three independent experiments;
bars,S E( right panel); #, P\0.05 compared with parental wild-type
cells)
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123decrease of luciferase activity, indicating that all of these
sites are necessary for regulation of IL-8 expression in
U87vIII cells.
An attempt to identify CypA-associated transcription
factors involved in regulation of the IL-8 promoter in the
CypA KD cell line was unsuccessful, due to very low basal
levels of IL-8 production. Therefore, we examined whether
inhibition of CypA isomerase activity is able to suppress
TNFa-induced IL-8 expression in the wild-type U87vIII
cells. Cells were treated with CsA, which inhibits CypA
isomerase and calcineurin phosphatase activity. Cells were
also treated with rapamycin as a control, since rapamycin
binds to FKBP-12 but not a calcineurin inhibitor. As shown
in Fig. 7C, when the cells transfected with the reporter
plasmid driven by the wild type IL-8 promoter were treated
with TNFa, luciferase activity increased markedly. This
increase was inhibited by CsA but not rapamycin, indi-
cating that CypA isomerase activity is associated with
regulation of IL-8 expression in U87vIII cells.
NF-jB activity decreases in CypA KD cells
To further identify the transcription factors responsible for
down-regulation of IL-8 expression; we performed EMSAs
on nuclear extracts from the CypA KD clones, Ud-3 and
Ud-12, to compare to those isolated from parental U87vIII
cells and SC. When the NF-jB oligo was used as probe, the
density of the protein/DNA complex in CypA KD clones
was much lower than in the parental U87vIII cells and SC
(Fig. 8a). In contrast, when C/EBP and AP1 oligos were
used as probes, no alteration was observed when subjecting
these cells to EMSA (Fig. 8b and c). We next examined
whether CypA KD affects expression and phosphorylation
of IjBa, using Western blot analysis. As shown in Fig. 8d
(upper panel), the levels of phosphorylated IjBa are lower
in CypA KD clones than in wild-type cells and SC,
whereas the levels of IjBa in the wild-type cells and SC
are lower than in the CypA KD clones. In Fig. 8d (lower
Fig. 4 CypA KD correlates with increased apoptosis under the
condition of serum withdrawal. The CypA KD single clones, Ud-3
and Ud-12, and parental U87vIII control cells were grown in 96-well
plates in media without serum for 6 days. Cells (10,000/well) were
plated in replicates of three. Viable cells were measured at the
indicated time points by MTT assays. Columns, mean of the relative
OD 595 nm readings from three independent experiments; bars, SE;
*, P\0.05 compared with parental wild-type cells
Fig. 5 CypA KD-mediated down-regulation of IL-8 expression. a
IL-8 expression levels were determined by a quantitative real-time
PCR analysis. One microgram of total RNA was used for cDNA
synthesis, using Superscript III (Invitrogen) with the oligo(dT)15
primer. Quantitative real-time PCR (QRT-PCR) was performed using
the Power SYBR Green PCR Master Mix (Applied Biosystem)
detected by the 7300 Real Time PCR System (Applied Biosystems).
The relative expression of IL-8 mRNA normalized to the internal
reference 18S rRNA was analyzed using the 2
-DDCT method
(columns, mean of results from three independent experiments; bars,
SE; *, P\0.05 compared with parental wild-type cells). b IL-8
ELISA. Cells were seeded into 24-well plates for 24 h. Cell media
was collected for measurement of IL-8 expression according the
manufacturer’s protocol (columns, mean of results from three
independent experiments; bars, SE; *, P\0.05 compared with
parental wild-type cells)
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123panel), nuclear p65 is lower in CypA KD clones than in
wild-type cells and SC, which clearly indicated less nuclear
translocated NF-jB in the CypA KD cells and further
conﬁrmed our observation above when using EMSA.
Discussion
It has been suggested that CypA may contribute to the
pathology of human malignancies. Indeed, several experi-
ments have demonstrated that CypA is substantially up-
regulated in various types of cancers and cancer cell lines,
including pancreatic adenocarcinoma [17], non-small cell
lung cancer [18], hepatocellular carcinoma [33], endome-
trial carcinoma [19], and esophageal squamous cell carci-
noma [20]. These over-expressed CypA molecules mediate
multiple cellular processes and confer growth advantage to
tumor cells in the neoplastic microenvironment. Further
investigation of the connection between CypA and cancer
has led to the conclusion that over-expressed CypA is
strongly correlated with malignant lung cancer cells [21,
34]. Our data obtained with glioblastoma cell lines also
support this concept. A previous report has demonstrated
that over-expression of CypA in the SILEK-transformed
small airway epithelial cell line correlates with dramati-
cally faster tumor formation in vivo [34], this suggests that
the effects of CypA deﬁciency may have important
implications for the treatment of aggressive tumor growth.
Our data shows strong evidence that CypA KD leads to
decreased cell proliferation in vitro and slower tumor
growth in vivo (Fig. 2). Similarly, CypA KD increases
apoptosis under the condition of serum withdrawal (Fig. 4),
this is a reverse effect for over-expression of CypA in
cancer cells renders resistance to anticancer drugs and
hypoxia-induced cell death [22, 23]. These results not only
establish the relevance of CypA to tumorigenesis, but also
substantiate the logic of down-regulating CypA as an
approach for treatment of cancer patients.
Over-expression of CypA in rheumatoid arthritis stim-
ulates production of inﬂammatory cytokines such as TNF-a,
IL-1b, IL-8, MCP-1, and MMP-9 [25]. These CypA-stim-
ulated products could occur through a pathway that is
dependent on NF-jB activation. However, the mechanism
by which CypA mediates signaling to activate NF-jB
remains to be investigated. Similarly, stably expressed
CypA in the SK-Hep1 cell line revealed that CypA
Fig. 6 Expression of a siRNA-resistant wild-type CypA rescue
expression plasmid restores IL-8 expression and cell proliferation
defects. a Western blot analysis of endogenous CypA and exogenous
myc-tagged CypA. U87vIII cells (WT) and CypA KD clone Ud-12
were transfected with the pcDNA3.1/Myc.His vector (vector) or the
rescue construct (resc_CypA). Five micrograms of each cell extract
were subjected to Western blot analysis probing with anti-CypA and
anti-myc antibodies. b Real-time PCR analysis of the IL-8 mRNA.
The values plotted are the mean of three separate experiments. c MTT
assay of cell proliferation. At various time points, cells were subjected
to MTT assays. The absorbance in each well was measured at 595 nm
in a microtiter plate reader. Bars indicate the standard error from three
individual experiments
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123up-regulates the expression of many cytokine-related genes
such as IL-8, IL-1b, and IL-6 [22]. These up-regulated
cytokines and chemokines may confer tumor cell growth
advantage in the neoplastic microenvironment. With these
observations in mind, it is conceivable that over-expression
of CypA in glioblastomas would lead to highly expressed
IL-8. Indeed, in human glioblastoma, IL-8 is expressed and
secreted at high levels, and has been suggested to be crit-
ical to glial tumor neovascularity and progression [26]. Our
data demonstrate that CypA KD in the U87vIII glioblas-
toma cell line results in profoundly down-regulated IL-8
expression (Fig. 5), suggesting that a strategy to knock
down endogenous over-expressed CypA could prevent
tumor progression.
IL-8 is known to possess tumorigenic and proangiogenic
properties. Down-regulation of IL-8 or its regulatory sig-
naling within the tumor microenvironment would have
signiﬁcant therapeutic potential in modulating tumor pro-
gression. A recent report indicated that exposure of U251
glioblastoma cells to calcium inonophore and phorbol-
myristate-acetate (PMA) led to dramatic increases in IL-8
expression, which was suppressed by the calcineurin
inhibitor, CsA and FK506 [35]. CsA is a CypA inhibitor;
therefore, CsA suppression of IL-8 expression may con-
tribute to our observation that CypA KD results in down-
regulation of IL-8 expression.
The study conducted in human monocytic leukemia cell
line THP-1 demonstrated that CypA induces degradation of
IjB and nuclear translocation of NF-jB[ 25]. Our data
concur with their report that CypA KD decreased NF-jB
binding activity, decreased phosphorylation and degrada-
tion of IjBa, reduced nuclear translocation of NF-jB
(Fig. 8d), and led to down-regulation of IL-8 expression.
Correspondingly, human recombinant CypA increased
phosphorylation of IjBa and stimulated activation of NF-
jB in endothelial cells [36]. However, the means by which
CypA mediates signaling to activate NF-jB remains to be
investigated. A physical and functional map of the human
TNF-a/NF-jB signal transduction pathway identiﬁed
FK506-binding protein 51 (FKBP51), an immunophilin
Fig. 7 Analysis of IL-8
promoter and regulation of IL-8
expression by TNFa and CsA.
a The schematic IL-8 luciferase
reporter constructs used in this
study. The luciferase reporter
plasmids driven by wild-type
IL-8 promoter and the mutated
promoters containing mutated
NF-jB, C/EBP, or AP1 site are
designated as wt_IL-8, mt_NF-
jB, mt_C/EBP, and mt_AP1,
respectively. b U87vIII cells
were transfected with indicated
reporter plasmids together with
Renilla luciferase plasmid.
Luciferase activity was
measured at 24 h post-
transfection (columns, mean of
results from three independent
experiments; bars, SE).
c U87vIII cells were transfected
with the reporter plasmid driven
by the wild type IL-8 promoter
together with Renilla luciferase
plasmid. At 24 h post-
transfection, cells were
incubated with 1 lg/ml CsA or
rapamycin for 5 h, then
stimulated by 10 ng/ml TNF-a
for another 4 h. Cells were then
harvested and promoter activity
was determined. Results are
presented as relative reporter
activity after normalization to
Renilla luciferase activity. Bars
indicate the standard error of
three replicates
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IKKa. This interaction was conﬁrmed by co-immunopre-
cipitation [37]. The NCBI protein data bank shows that
IKKa and IKKb contain a potential CypA-binding con-
sensus sequence, FRPFLP/FGPXLP. Binding of CypA to
IKKa and IKKb may affect the phosphorylation at Ser 177
and Ser 181 residues that is necessary to activate kinase
activity. The possible interaction between CypA and IKKa
or IKKb is currently under investigation.
The present data obtained with both knock down and an
ectopically over-expressed rescue plasmid demonstrated
that down-regulation and restored IL-8 expression are
CypA-dependent (Fig. 6). Although there is no CypA-
binding motif in the IL-8 promoter to regulate IL-8
expression, CypA-associated IL-8 production may be reg-
ulated by other transcription factors in an indirect manner.
Transcriptional regulation of IL-8 has been studied exten-
sively at the level of its promoter region, which contains
cis-acting elements for transcription factors C/EBP, AP-1
and NF-jB. Using a wild-type and a series of mutants of
IL-8 promoter luciferase constructs, we have found that all
three binding sites are important positive regulatory ele-
ments for regulation of IL-8. These data suggest that
multiple factors are required to work in concert for optimal
IL-8 expression in glioblastoma cells. Using EMSA, we
found decreased binding of NF-jB to the IL-8 promoter
cis-acting element when using nuclear extracts isolated
from CypA KD clones (Fig. 8a). These data suggest that
CypA is associated with NF-jB binding activity. Taken
together, it has been shown that CypA KD leads to
decreased NF-jB binding, followed by suppression of a
synergistically functional interaction between all three
transcription factors resulting in reduced IL-8 expression.
Our data demonstrate that knockdown of CypA KD-med-
iated decreases of cell proliferation, inﬁltration, and tumor
formation may occur through down-regulating IL-8. Thus,
Fig. 8 Reduced NF-jB binding
activity and decreased p65
associated with CypA KD cells.
a, b, and c EMSA assays were
performed using nuclear
extracts from U87vIII cells
(WT), scrambled control cells
(SC), and the CypA KD clones,
Ud-3 and Ud-12, with NF-jB,
C/EBP, or AP1 oligos as probes.
For competition experiments,
protein was pre-incubated with
100-fold molar excess of
unlabeled oligos at 25C for
10 min before addition of
labeled probes. p84 expression
on Western blots was used as
loading control for EMSA. d
Cytoplasmic extracts (CE)
prepared from U87vIII cells
(WT), scrambled control cells
(SC), and the CypA KD clones,
Ud-3 and Ud-12, were
immunoblotted for
phosphorylated IjBa (p-IjBa)
and IjBa, and actin was used as
the internal control (upper
panel). Nuclear extracts (NE)
were subjected to Western blot
analysis probing with anti-p65
antibody. p84 was used as an
internal control (lower panel)
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123targeted knockdown of CypA could be an effective thera-
peutic approach against devastating glioblastomas.
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